Next-generation sequencing to dissect hereditary nephrotic syndrome in mice identifies a hypomorphic mutation in Lamb2 and models Pierson’s syndrome

Katherine R Bull,1 Thomas Mason,1 Andrew J Rimmer,1 Tanya L Crockford,1,2 Karlee L Silver,1 Tiphaine Bourniez-Jones,1 Tertius A Hough,4 Shirine Chaudhry,5 Ian SD Roberts,6 Christopher C Goodnow3 and Richard J Cornall1,2*

1 Nuffield Department of Medicine and Wellcome Trust Centre for Human Genetics, Oxford University, UK
2 MRC Human Immunology Unit, Weatherall Institute for Molecular Medicine, Oxford University, UK
3 Department of Immunology, John Curtin School of Medical Research, Australian National University, Canberra, Australia
4 MRC Harwell, Harwell Science and Innovation Campus, Oxfordshire, UK
5 Australian Phenomics Facility, Australian National University, Canberra, Australia
6 Oxford University Hospitals NHS Trust, John Radcliffe Hospital, Headington, Oxford, UK

*Correspondence to: RJ Cornall, Centre for Cellular and Molecular Physiology, Wellcome Trust Centre for Human Genetics, Roosevelt Drive, Oxford OX3 7BN, UK. E-mail rcornall@well.ox.ac.uk

Abstract

The study of mutations causing the steroid-resistant nephrotic syndrome in children has greatly advanced our understanding of the kidney filtration barrier. In particular, these genetic variants have illuminated the roles of the podocyte, glomerular basement membrane and endothelial cell in glomerular filtration. However, in a significant number of familial and early onset cases, an underlying mutation cannot be identified, indicating that there are likely to be multiple unknown genes with roles in glomerular permeability. We now show how the combination of N-ethyl-N-nitrosourea mutagenesis and next-generation sequencing could be used to identify the range of mutations affecting these pathways. Using this approach, we isolated a novel mouse strain with a viable nephrotic phenotype and used whole-genome sequencing to isolate a causative hypomorphic mutation in Lamb2. This discovery generated a model for one part of the spectrum of human Pierson’s syndrome and provides a powerful proof of principle for accelerating gene discovery and improving our understanding of inherited forms of renal disease.

Keywords: proteinuria; nephrotic syndrome; congenital nephrosis; kidney glomerulus; glomerular basement membrane; next-generation sequencing; mutagenesis; animal model

Received 13 August 2013; Revised 15 November 2013; Accepted 21 November 2013

No conflicts of interest were declared.

Introduction

Twenty percent of paediatric patients with the nephrotic syndrome fail to achieve remission with steroid treatment [1], and these patients have a high incidence of progression to end-stage kidney disease [2]. In contrast to the more common form of the disease, the steroid-resistant nephrotic syndrome (SRNS) is predominantly monogenic, involving at least 24 known genes [3], including NPHS1 [4], NPHS2 [5], WT1 [6], LAMB2 [7], CD2AP [8], PLCE1 [9], ACTN4 [10], TRPC6 [11] and INF2 [12]. These targets have highlighted the key role of the podocyte in maintaining the integrity of the glomerular filtration barrier [13] and the importance of the endothelial cell and the extracellular glomerular basement membrane (GBM), which is composed of collagen IV, laminin, heparan sulphate proteoglycans and nidogen-1, in maintaining selective permeability [14,15]. The mutations causing SRNS have revealed diverse and sometimes unexpected functions, ranging from ion channels to the organization of the actin cytoskeleton or mitochondrial function. In 20–40% of familial cases of childhood-onset SRNS [16–18] and at least 30% of all cases within the first year of life [19,20], the underlying gene is not known. Combined with the diversity of genes and pathways already identified, this suggests there are many unknown genes contributing to the filtration barrier, with potential as therapeutic targets [21].

Whilst future studies using next-generation sequencing will undoubtedly identify more of the genes involved in familial cases of SRNS, such families are rare, and it is therefore possible that a simultaneous and
complementary approach using animals could accelerate the discovery of new genes and provide models for human disease. In particular, forward screens using the chemical mutagen \(N\)-ethyl-\(N\)-nitrosourea (ENU) are a powerful method to identify genes without \textit{a priori} assumptions as to pathways or function, by inducing random point mutations that mimic human variation. The aim of this study was to establish an efficient method to identify genetic variants causing proteinuria in a mouse model, using ENU mutagenesis. By harnessing whole-genome sequencing (WGS), we were able to rapidly isolate the causative mutation in an ENU pedigree with the nephrotic syndrome.

Materials and methods

ENU and phenotyping

\textit{Nephertiti} mice were generated at the Australian Phenomics Facility, Australian National University, Canberra. C57BL/6J (B6) founder mice were treated with three doses of 90–100 mg/kg \(N\)-ethyl-\(N\)-nitrosourea (Sigma), as previously described [22]. Proteinuria was detected by urine dipstick (Multistix, Bayer Health Care) in third-generation (G3) offspring from such a founder.

Collection of blood samples

Mice aged 17–25 weeks were terminally anaesthetized and blood samples were collected, by cardiac puncture, into lithium heparin paediatric tubes and centrifuged to separate out the plasma.

Routine clinical chemistry of plasma samples

Clinical chemistry was performed on a Beckman Coulter AU400 semi-automated clinical chemistry analyser by the Mary Lyon Centre’s clinical pathology service laboratory at MRC Harwell. All assays were carried out using the manufacturer’s instructions, parameter settings and reagents. Samples were analysed for total protein, albumin, total cholesterol, triglycerides urea and creatinine. Electrolytes (sodium, potassium and chloride), total calcium, inorganic phosphate, alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, HDL cholesterol, LDL cholesterol and glucose were also measured.

Histology

Tissue sections were fixed in 10% neutral buffered formalin, embedded in paraffin, cut to 3 \(\mu\)m sections and stained with either haematoxylin and eosin (H&E), periodic acid–Schiff (PAS) or methenamine silver, according to published methods. For transmission electron microscopy, tissue was fixed with gluteraldehyde, embedded with resin and sectioned at 70 nm. The Oxford Centre for Histopathology Research performed the electron microscopy and silver staining. IgG immunofluorescence was performed on formalin-fixed tissues, following pronase antigen retrieval [23] using fluorescein isothiocyanate (FITC)-conjugated IgG (Caltag) [24]. 4’,6-Diamidino-2-phenylindole (DAPI) was used for nuclear counterstaining. Immunofluorescence images were captured using a Zeiss 510 metahead confocal microscope.

DNA extraction

DNA was extracted from tail tissue using a DNAeasy kit (Qiagen), and quantified using a Qubit fluorometer (Invitrogen).

Conventional mapping

B6 mice were out-crossed to the CBA/J strain for mapping and bred to bring the causative mutation to homozygosity, using dipstick urine testing to track the phenotype. Linkage mapping was performed using simple sequence-length polymorphisms (SSLP) and single nucleotide polymorphisms (SNPs) (Figure 2A, B). Maximal LOD scores [25] using a range of recombination fractions <0.5 were calculated at each of 26 polymorphic loci, given the observed alleles in a mean of 27 affected and unaffected mice from the \textit{nephertiti} pedigree.

Whole-genome sequencing and mapping

Whole-genome sequencing was performed on one lane of a HiSeq 2000 (Illumina) to 5.8× mean coverage, using paired-end 100 bp reads. Reads were mapped with Stampy [26] against the MGSCv37 mouse reference genome; 92.7% of the genome was covered by at least one read. Variants were called with Platypus (Rimmer A, Mathieson I, Lunter G, McVean G, (2012) Platypus: An Integrated Variant Caller www.well.ox.ac.uk/platypus) and filtered against an in-house union file of variants seen in other ENU mouse pedigrees, and against dbSNP v 128. The variants were also filtered for coverage depth, allelic or strand bias, homopolymers, repetitive sequence and quality of local variation. In-house Python scripts were used for all filtering steps.

An in-house algorithm based on a hidden Markov model [27] was used to infer the most likely ancestral haplotypes inherited by the sequenced \textit{nephertiti} mouse, based on the observed frequency of variants and knowledge of the ENU mutation rate [28]; for details, see Supplementary material. A bam format file containing the read data for this experiment will be made freely available in the European Nucleotide Archive data repository.

Validation of the \textit{Lamb2} mutation with Sanger sequencing

Whole genomic DNA from the sequenced mouse was amplified using oligonucleotide primers (forward CTATGCTGGTGGAGCGTTCT, reverse TGAG- TAGCGGGACTCACACA) and Biotaq polymerase.

© 2013 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain and Ireland. www.pathsoc.org.uk J Pathol 2014; 233: 18–26 www.thejournalofpathology.com
(Bioline Reagents Ltd). Amplification of the PCR product was carried out using BigDye reagents (Applied Biosystems) and sequenced on an ABI Prism 3100 machine.

Statistical analyses

LOD score calculations were as described above, all other statistical analyses were performed using the GraphPad Prism package. WT-to-mutant \( p \) values for clinical chemistry were calculated using unpaired two-tailed \( t \)-tests.

Ethics

All animal experiments were approved by local and national ethical review, including the Australian National University Animal Ethics and Experimentional Committee and the Oxford University Local Ethical Review Committee and UK Home Office (License No. PPL 30/2455).

Results

In the course of a programme screening third-generation offspring of ENU-treated mice for immune phenotypes [29], we detected several mice from a single pedigree with heavy proteinuria on dipstick testing, which was detectable at weaning (3 weeks of age) and inherited in an autosomal recessive manner (Figure 1A). The nephertiti mouse strain exhibited a nephrotic phenotype. Mice examined between 17 and 25 weeks had hypoproteinaemia and hyperlipidemia, raised cholesterol and triglycerides and low body weight in comparison to wild-type (WT) B6 mice. Urea and creatinine were not significantly different and protein casts were identified in the affected mice reduced this to one candidate, a G–A transition at position 108 383 650 on chromosome 9, predicted to result in a C185Y amino acid substitution in exon 5 of the laminin-\( \beta 2 \) protein.

Mutations in human \( \text{LAMB2} \) cause Pierson’s syndrome, which typically presents with severe nephrotic syndrome alongside ocular abnormalities and neuromuscular hypertonia [7]. Since \( \text{LAMB2} \) knock-out mice exhibit nephrotic range proteinuria [30], both the clinical and animal data suggest that this mutation is causative in nephertiti.

Although this result demonstrated that WGS combined with linkage data could isolate the causative mutation, we wanted to examine the efficacy of a WGS approach without utilizing conventional linkage information. To do this, we developed an algorithm to identify all genomic intervals inherited from the ENU-treated founder, based on the density of variants (see Supplementary material). The algorithm identified regions comprising 263 Mb as having two alleles inherited from the ENU-treated founder, including the \( \text{LAMB2} \) mutation. Sanger sequencing confirmed the mutation (Figure 4C), which is highly conserved and predicted deleterious by Polyphen-2 [31].

Discussion

Laminin forms the basic scaffold protein of basement membranes, as cruciform heterotrimers composed of \( \alpha \), \( \beta \) and \( \gamma \) subunits. The principal laminin of adult GBM is composed of \( \alpha 5 \), \( \beta 2 \) and \( \gamma 1 \) subunits [32] and is also expressed at the neuromuscular synapse [33]. The mutation in nephertiti lies in the globular N-terminal domain on the short arm of laminin-\( \beta 2 \), which is important for trimer polymerization [34] (Figure 4D).

\( \text{LAMB2}^{-/-} \) mice have severe neuromuscular disease, which contributes to their perinatal lethality; but when transgenic laminin-\( \beta 2 \) is expressed in skeletal muscle (MCK-B2), the mice develop proteinuria and die.
A hypomorphic mutation in Lamb2

of kidney failure at 1 month [35]. In contrast, the nephertiti mice survive beyond 6 months. All mice homozygous for the nephertiti allele had 3+ or 4+ protein on dipstick testing (Figure 1A), consistent with 3–10 mg/ml or > 10 mg/ml urinary protein, respectively [36], and comparable with the 10 mg/ml reported in Lamb2−/−-null mice [37]. Therefore, the prolonged survival in nephertiti mice appears to be due to preserved renal function despite nephrosis (Figure 1F, G), and different from the effects of the null mutation [38]. This would be consistent with a hypomorphic mutation, with mutant laminin β2 expressed in the GBM, and suggests that the defect in nephertiti mice may be due to abnormal function of the mutant protein.

The nephertiti phenotype is consistent with the spectrum of human Pierson’s syndrome. Patients with truncating null mutations develop mesangial sclerosis and end-stage renal failure within the first few years of life, often combined with complex ocular abnormalities and severe psychomotor retardation [39]. However, several groups have identified patients with missense mutations in LAMB2, which are associated with slower renal progression and in some cases absence of extrarenal manifestations [40–43]. The latter would be consistent with the phenotype in nephertiti, where survival, breeding, locomotor function and behaviour appear to be normal. The human missense mutations are clustered at the globular N-terminal domain [44], and some have been shown to result in low levels of laminin β2 in the GBM [42]. In contrast, damaging premature stop codons are distributed across the gene, and deletion of even the last 39 amino acids results...
Figure 2. Renal light microscopy and electron microscopy in WT (A, C, E, G) and nephertiti (B, D, F, H) mice. (A, B) After H&E staining, at objective magnification ×20, nephertiti mice show dilated renal tubules containing protein casts (arrow) and protein resorption droplets in tubular epithelium (arrowhead). (C, D) After methenamine silver staining, at objective magnification ×60, nephertiti mice show prominent membrane spikes (arrow). (E, F) By electron microscopy, at magnification ×18 500, nephertiti mice show irregularly thickened glomerular basement membranes (arrowhead). (G, H) Higher-power images of basement membrane in (E, F), with subepithelial spikes and podocyte foot process effacement in nephertiti (arrow). All histology is shown in homozygous affected nephertiti mice and WT unaffected siblings. Histology is representative of samples from three affected and three WT for each stain.

in complete loss of protein expression [7], presumably because the C-terminus is required for trimer assembly [45].

The mechanism by which missense mutations in the N-terminal domain induce the nephrotic syndrome is not fully understood. Polymerization through binding of these domains is mediated via C-terminal interactions with dystroglycan and integrin receptors in vitro, driving reciprocal cytoskeletal assembly and actin reorganization [46] and suggesting that correct polymerization of laminin could involve podocyte signalling. The filtration barrier failure observed with podocyte-specific knockout of the integrin-linked kinase ILK also points to a role for the interaction between laminin in the GBM and podocyte integrin [47]. The prominence of membrane spikes in nephertiti closely resembles mice lacking the tetraspanin CD151, in which lack of integrin α3β1–CD151 interactions may also result in podocyte detachment and compensatory production of excess GBM components [48]. The fact that over-expression of laminin β1 can partially rescue the Lamb2−/− phenotype [49], albeit an incomplete rescue, despite adequate laminin trimer formation, indicates that laminin β2 has unique
A hypomorphic mutation in \textit{Lamb2}

**Figure 3.** Mapping the \textit{nephertiti} mutation to chromosome 9. (A) Coarse mapping using SSLP. (B) Fine mapping using SSLP and SNPs. The only SNP with fully consistent linkage to the homozygous phenotype is shown boxed; the limits of the linkage region are defined by the adjacent SNPs.

- Proteinuria precedes foot process effacement in \textit{Lamb2}−/− mice, suggesting that the defect is at least partly GBM-intrinsic[38]. Consistent with this, we found relative preservation of podocyte structure in \textit{nephertiti}, despite GBM thickening and the nephrotic syndrome. Changes in one component of the GBM can affect others, for example in Alport’s syndrome, where mutations in collagen IV result in ectopic expression of laminin [51]; however, \textit{Lamb2}−/− mice have normal collagen IV chain expression [30].

- A transgenic N-terminal mutant laminin-β2 only partially rescues the \textit{Lamb2}−/− phenotype, with low levels of β2 at the GBM attributed to failure to secrete the protein [52], and moderate transgene expression resulting in a moth-eaten, irregularly thickened GBM, similar to \textit{nephertiti}. The transgenic C321R mutation results in misfolding in the endoplasmic reticulum and death due to renal failure by 3 months [53].

The preserved function and prolonged survival in \textit{nephertiti} may be due to the more physiological expression of the mouse protein; alternatively, the C185Y mutation, which unlike C321R lies N-terminal to the disulphide-bonded cysteines of the EGF-like repeats, may have lesser consequences for protein folding.

- Whereas \textit{nephertiti} was generated on a B6 background, the targeted knockout \textit{Lamb2}−/− was originally from 129 s1/SvJ ES cells and could therefore carry 129 specific modifiers in linkage to the \textit{Lamb2} gene on a B6 background. Although formal proof would require analysis of a \textit{Lamb2}−/− on a pure B6 background, we think it unlikely that linked genes in the congenic region have important modifier effects: first, because it is possible to effect a partial rescue of the renal-specific \textit{Lamb2}−/− mice, originally from 129 ES cell origin, with a B6CBAF2/J mutant transgene [52]; and second, because we did not observe any

© 2013 The Authors. \textit{The Journal of Pathology} published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain and Ireland. www.pathsoc.org.uk www.thejournalofpathology.com
A hypomorphic laminin β2 mutation is the cause of proteinuria in nephertiti. (A) Scatter plots of homozygous (red) and heterozygous (blue) filtered WGS variants for each chromosome. High-density regions correspond to the CBA genomic regions; regions inheriting both alleles from the ENU-treated founder have a lower density of homozygous variation than CBA regions but higher than background variation from the reference in WT genomic intervals. The region identified by conventional linkage mapping is shaded yellow. Regions identified as homozygous ENU in this mouse by variant density using the hmm algorithm are shaded pink. Black circles indicate candidate coding variants affecting protein sense, the Lamb2 variant is shown as a pink circle. (B) Candidate variants identified by WGS without reference to the conventional linkage region include the causative mutation. (C) Sanger sequencing confirms the Lamb2 mutation. (D) The mutation induces a C-to-Y substitution in the globular N-terminal domain (LN) of laminin β2, on the β2 short arm of the laminin 521 heterotrimer.

Phenotypic consequences following outcrossing to the CBA/J strain for mapping in nephertiti.

Laminin is thought to be produced by both podocytes and endothelial cells in the glomerulus [54]; however, glomerular hybrid experiments suggest that cellular origin influences laminin localization within the GBM [55]. Access to a mutant strain expressing a hypomorphic form of laminin β2 under its physiological promoter will make it possible to isolate such cell-specific effects.

ENU mutagenesis coupled to high-throughout sequencing offers two advantages for the discovery of new genes involved in the development or maintenance of the glomerular filtration barrier, which are illustrated by our study. First, point mutations induce viable phenotypes that mimic human disease, so nephertiti models the milder spectrum of Pierson’s syndrome and confirms the importance of the N-terminal domain in laminin β2 function. Second, it is now possible, using WGS, to move rapidly from phenotypic screens for proteinuria, urinary protein:creatinine ratio, renal clearance, histology or imaging to the identification of causative mutations. Future screens based on these principles will identify novel genes, variants and pathways involved in heritable forms of human renal disease and provide tools for investigating the underlying mechanisms that cause pathology.

Acknowledgements

The authors thank the High-throughput Genomics Group at the Wellcome Trust Centre for Human...

Figure 4. A hypomorphic laminin β2 mutation is the cause of proteinuria in nephertiti. (A) Scatter plots of homozygous (red) and heterozygous (blue) filtered WGS variants for each chromosome. High-density regions correspond to the CBA genomic regions; regions inheriting both alleles from the ENU-treated founder have a lower density of homozygous variation than CBA regions but higher than background variation from the reference in WT genomic intervals. The region identified by conventional linkage mapping is shaded yellow. Regions identified as homozygous ENU in this mouse by variant density using the hmm algorithm are shaded pink. Black circles indicate candidate coding variants affecting protein sense, the Lamb2 variant is shown as a pink circle. (B) Candidate variants identified by WGS without reference to the conventional linkage region include the causative mutation. (C) Sanger sequencing confirms the Lamb2 mutation. (D) The mutation induces a C-to-Y substitution in the globular N-terminal domain (LN) of laminin β2, on the β2 short arm of the laminin 521 heterotrimer.

Phenotypic consequences following outcrossing to the CBA/J strain for mapping in nephertiti.

Laminin is thought to be produced by both podocytes and endothelial cells in the glomerulus [54]; however, glomerular hybrid experiments suggest that cellular origin influences laminin localization within the GBM [55]. Access to a mutant strain expressing a hypomorphic form of laminin β2 under its physiological promoter will make it possible to isolate such cell-specific effects.

ENU mutagenesis coupled to high-throughout sequencing offers two advantages for the discovery of new genes involved in the development or maintenance of the glomerular filtration barrier, which are illustrated by our study. First, point mutations induce viable phenotypes that mimic human disease, so nephertiti models the milder spectrum of Pierson’s syndrome and confirms the importance of the N-terminal domain in laminin β2 function. Second, it is now possible, using WGS, to move rapidly from phenotypic screens for proteinuria, urinary protein:creatinine ratio, renal clearance, histology or imaging to the identification of causative mutations. Future screens based on these principles will identify novel genes, variants and pathways involved in heritable forms of human renal disease and provide tools for investigating the underlying mechanisms that cause pathology.

Acknowledgements

The authors thank the High-throughput Genomics Group at the Wellcome Trust Centre for Human...
A hypomorphic mutation in LamB2

Genetics for the generation of the whole-genome sequencing data. We acknowledge the contribution to this study made by the Oxford Centre for Histopathology Research, supported by the NIHR Oxford Biomedical Research Centre, who performed silver staining and electron microscopy. We thank staff at the Australian Phenomics facility and the Oxford Biomedical Research Service for animal husbandry. The High-throughput Genomics Group at the Wellcome Trust Centre for Human Genetics is funded by the Wellcome Trust (Grant No. 090532/Z/09/Z) and the Medical Research Council (MRC; Hub Grant No. G0900747 91070). This study was supported by the Wellcome Trust (Strategic Award No. 082030, to CCG; and Studentship No. 094446/Z/10/Z, to KRB), the Oxford NIHR Biomedical Research Centre and the MRC Human Immunology Unit (to RJC). AJR was supported by the Wellcome Trust (Grant No. 090532/Z/09/Z).

Author contributions

KRB and RJC designed the experiments; TM, TLC, KLS, TB-J and SC carried out phenotyping and mapping experiments; TM, TB-J, KLS and KRB prepared histology samples; KRB performed immunofluorescence experiments; TAH performed clinical chemistry analysis; ISDR reviewed and reported the histopathology; CCG provided ENU-treated animals and initial analysis; ISDR reviewed and reported the histopathology; CCG provided ENU-treated animals and initial analysis; ISDR reviewed and reported the histopathology; TAH performed clinical chemistry analysis; CCG provided ENU-treated animals and initial analysis; ISDR reviewed and reported the histopathology; TAH performed clinical chemistry analysis; CCG provided ENU-treated animals and initial analysis; CCG; and RJC interpreted the data; and KRB and RJC interpreted the data and wrote the paper. All authors had final approval of the submitted and published versions.

References

1. Wong W. Idiopathic nephrotic syndrome in New Zealand children, demographic, clinical features, initial management and outcome after twelve-month follow-up: results of a three-year national surveillance study. J Paediatr Child Health 2007; 43(5): 337−341.
2. Mekahli D, Liutkus A, Ranchin B, et al. Long-term outcome of idiopathic steroid-resistant nephrotic syndrome: a multicenter study. Pediatr Nephrol 2009; 24(8): 1525−1532.
3. Kopp JB. An expanding universe of FSGS genes and phenotypes: LMX1B mutations cause familial autosomal dominant FSGS lacking extrarenal manifestations. J Am Soc Nephrol 2013; 24(8): 1183−1185.
4. Kestila M, Lenkkeri U, Mannikko M, et al. Positionally cloned gene for a novel glomerular protein – nephrin – is mutated in congenital nephrotic syndrome. Mol Cell 1998; 1(4): 575−582.
5. Bouté N, Gribouval O, Roselli S, et al. NPHS2, encoding the glomerular protein podocin, is mutated in autosomal recessive steroid-resistant nephrotic syndrome. Nat Genet 2000; 24(4): 349−354.
6. Barbaus S, Niaudet P, Gubler MC, et al. Donor splice-site mutations in WT1 are responsible for Frasier syndrome. Nat Genet 1997; 17(4): 467−470.
7. Zener M, Aigner T, Wendler O, et al. Human laminin β2 deficiency causes congenital nephropathy with mesangial sclerosis and distinct eye abnormalities. Hum Mol Genet 2004; 13(21): 2625−2632.
8. Gigante M, Pontrelli P, Montemurro E, et al. CD2AP mutations are associated with sporadic nephrotic syndrome and focal segmental glomerulosclerosis (FSGS). Nephrol Dial Transpl 2009; 24(6): 1858−1864.
9. Hinkes B, Wiggins RC, Gbadejesin R, et al. Positional cloning uncovers mutations in PLCE1 responsible for a nephrotic syndrome variant that may be reversible. Nat Genet 2006; 38(12): 1397−1405.
10. Kaplan JM, Kim SH, North KN, et al. Mutations in ACTN4, encoding α-actinin-4, cause familial focal segmental glomerulosclerosis. Nat Genet 2000; 24(3): 251−256.
11. Winn MP, Conlon PJ, Lynn KL, et al. A mutation in the TRPC6 cation channel causes familial focal segmental glomerulosclerosis. Science 2005; 308(5729): 1801−1814.
12. Brown EF, Schönhorst JS, Becker DJ, et al. Mutations in the formin gene INF2 cause focal segmental glomerulosclerosis. Nat Genet 2010; 42(1): 72−76.
13. Saleem MA. New developments in steroid-resistant nephrotic syndrome. Pediatr Nephrol 2013; 28: 699−709.
14. Chang CK, Inagi R. Glomerular diseases: genetic causes and future therapeutics. Nat Rev Nephrol 2010; 6(9): 539−554.
15. Minet JH. The glomerular basement membrane. Exp Cell Res 2012; 318(9): 973−978.
16. Santín S, Balíč G, Tazón-Vega B, et al. Clinical utility of genetic testing in children and adults with steroid-resistant nephrotic syndrome. Clin J Am Soc Nephrol 2011; 6(5): 1139−1148.
17. McCarthy HJ, Bierzynska A, Wherlock M, et al. Next generation sequencing (NGS) in the UK steroid resistant nephrotic syndrome (SRNS) study reveals complex genetic heterogeneity. Arch Dis Childhood 2012; 97(suppl 1): A161−A162.
18. Machuca E, Benoît G, Nevo F, et al. Genotype-phenotype correlations in non-Finnish congenital nephrotic syndrome. J Am Soc Nephrol 2010; 21(7): 1209−1217.
19. Hinkes BG, Mucha B, Vlangos CN, et al. Nephrotic syndrome in the first year of life: two-thirds of cases are caused by mutations in four genes (NPHS1, NPHS2, WT1, and LAMB2). Pediatrics 2007; 119(4): e907−e919.
20. Lee JH, Han KH, Lee H, et al. Genetic basis of congenital and infantile nephrotic syndromes. Am J Kidney Dis 2011; 58(6): 1042−1043.
21. Brinkkoetter PT, Ising C, Renzing T. The role of the podocyte in albumin filtration. Nat Rev Nephrol 2013; 9(6): 328−336.
22. Nelms KA, Goodnow CC. Genome-wide ENU mutagenesis to reveal immune regulators. Immunol 2001; 15(3): 409−418.
23. Nasr SH, Galgano SJ, Markowitz GS, et al. Immunofluorescence on promise-digested paraffin sections: a valuable salvage technique for renal biopsies. Kidney Int 2006; 70(12): 2148−2151.
24. Vinuesa CG, Cook MC, Angelucci C, et al. A RING-type ubiquitin ligase family member required to repress follicular helper T cells and autoimmunity. Nature 2005; 435(7041): 452−458.
25. Morton NE. Sequential tests for the detection of linkage. Am J Hum Genet 1955; 7(3): 277.
26. Lunter G, Goodson M. Stampy: a statistical algorithm for sensitive and fast mapping of Illumina sequence reads. Genome Res 2010; 20(16): 936−939.
27. Rabiner LR. A tutorial on hidden Markov models and selected applications in speech recognition. Proc IEEE 1989; 77(2): 257−286.
28. Bull KR, Rimmer AJ, Siggs OM, et al. Unlocking the bottleneck in forward genetics using whole-genome sequencing and identity by descent to isolate causative mutations. PLoS Genet 2013; 9(1): e1003219.
29. Vinuesa CG, Goodnow CC. Illuminating autoimmune regulators through controlled variation of the mouse genome sequence. Immunity 2004; 20(6): 669−679.
SUPPLEMENTARY MATERIAL ON THE INTERNET

The following supplementary material may be found in the online version of this article:
Details of the algorithm to identify genomic intervals inherited from the ENU founder
Figure S1. Expression of IgG in the kidney